key: cord-0908902-rdeosmhn
authors: Polk, Christopher; Sampson, Mindy; Jacobs, Anna; Kooken, Banks; Ludden, Tom; Passaretti, Catherine L; Leonard, Michael
title: Cholecystitis as a Possible Immunologic Consequence of COVID-19; Case Series from a Large Healthcare System
date: 2022-01-24
journal: Am J Med Sci
DOI: 10.1016/j.amjms.2022.01.008
sha: a99edb99adc3cddf0520f9ed069673f90b7756af
doc_id: 908902
cord_uid: rdeosmhn

nan

Gastrointestinal manifestations are seen in COVID-19 disease, but biliary disease has been less well described. 1 A few cases of cholecystitis have been described related to COVID-19 disease. [2] [3] [4] [5] The described cases of cholecystitis in individuals with SARS-CoV-2 were postulated to be mediated by a dysregulated immune response to SARS-CoV-2 infection. [2] [3] [4] [5] Two cases reporting cholecystitis related to COVID-19 were at onset of COVID-19 symptoms, 2 but most cases described cholecystitis lagging COVID-19 diagnosis by at least 10-14 days or longer. [3] [4] [5] This timing later in the COVID-19 disease course supports an immune mediated mechanism triggering biliary pathology. 6 

Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19

COVID-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall

COVID-19 with acute cholecystitis: a case report

Acute acalculous cholecystitis on a COVID-19 patient: a case report

Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Multisystem inflammatory syndrome in children: A systematic review

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

Multisystem Inflammatory Syndrome in Adults: Coming Into Focus

Mean Time from Dx to Surgery

All authors had full access to and take responsibility for the data reports. C.P., M.S., and M.L were responsible for the conception and design of the study, T.L. performed data extraction, and all authors contributed to data collection, writing, and revising the manuscript.

This work was not funded.

C.P. reports COVID-19 research funding from Atea, Gilead, Merck, and Regeneron.M.S reports COVID-19 research funding from Regeneron and Roche.No other authors have any conflicts to report.